Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-05-30
DOI
10.1111/cas.13655
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells
- (2018) Wen Hao Neo et al. BLOOD
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
- (2018) Lixin Wan et al. MOLECULAR CELL
- Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia
- (2017) S Fujita et al. LEUKEMIA
- Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
- (2017) C Pawlyn et al. Blood Cancer Journal
- Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
- (2016) Stefanie Göllner et al. NATURE MEDICINE
- An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
- (2016) George P Souroullas et al. NATURE MEDICINE
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
- (2016) H. Zhang et al. Cancer Discovery
- Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
- (2016) Prasoon Agarwal et al. Oncotarget
- Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
- (2016) Jacson K. Shen et al. Scientific Reports
- Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner
- (2015) M. Mochizuki-Kashio et al. BLOOD
- EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
- (2015) H. Hernando et al. MOLECULAR CANCER THERAPEUTICS
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
- (2014) T. Berg et al. BLOOD
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- Variant PRC1 Complex-Dependent H2A Ubiquitylation Drives PRC2 Recruitment and Polycomb Domain Formation
- (2014) Neil P. Blackledge et al. CELL
- EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
- (2014) William D. Bradley et al. CHEMISTRY & BIOLOGY
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
- (2014) Thomas De Raedt et al. NATURE
- PRC2 loss amplifies Ras signaling in cancer
- (2014) Annika Baude et al. NATURE GENETICS
- Histone H2A monoubiquitination promotes histone H3 methylation in Polycomb repression
- (2014) Reinhard Kalb et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non-Small Cell Lung Carcinoma
- (2013) C. Behrens et al. CLINICAL CANCER RESEARCH
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
- (2012) S. Tanaka et al. BLOOD
- RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3
- (2012) Lígia Tavares et al. CELL
- Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest
- (2012) Isabel Hidalgo et al. Cell Stem Cell
- Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
- (2012) Yi-Che Changchien et al. Journal of Translational Medicine
- PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes
- (2012) Zhonghua Gao et al. MOLECULAR CELL
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Polycomb repressive complex 2 is required for MLL-AF9 leukemia
- (2012) T. Neff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease
- (2012) A. Herrera-Merchan et al. Nature Communications
- RYBP and Cbx7 Define Specific Biological Functions of Polycomb Complexes in Mouse Embryonic Stem Cells
- (2012) Lluis Morey et al. Cell Reports
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells
- (2011) M. Mochizuki-Kashio et al. BLOOD
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
- (2011) Thomas De Raedt et al. CANCER CELL
- Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy
- (2011) D. Sasaki et al. HAEMATOLOGICA
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring
- (2010) Feng Xu et al. ANNALS OF HEMATOLOGY
- Regulation of Tumor Angiogenesis by EZH2
- (2010) Chunhua Lu et al. CANCER CELL
- Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
- (2010) Martin Sauvageau et al. Cell Stem Cell
- Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells
- (2010) H. Li et al. MOLECULAR CANCER RESEARCH
- Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
- (2010) Gorica Nikoloski et al. NATURE GENETICS
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- (2010) Thomas Ernst et al. NATURE GENETICS
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chromatin Signatures in Multipotent Human Hematopoietic Stem Cells Indicate the Fate of Bivalent Genes during Differentiation
- (2009) Kairong Cui et al. Cell Stem Cell
- Role of the polycomb protein EED in the propagation of repressive histone marks
- (2009) Raphael Margueron et al. NATURE
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
- (2008) Raphael Margueron et al. MOLECULAR CELL
- EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency
- (2008) Xiaohua Shen et al. MOLECULAR CELL
- Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
- (2008) Yutaka Kondo et al. NATURE GENETICS
- Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains
- (2008) Manching Ku et al. PLoS Genetics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More